These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 2565955)

  • 1. Development of dehydroemetine nanoparticles for the treatment of visceral leishmaniasis.
    Fouarge M; Dewulf M; Couvreur P; Roland M; Vranckx H
    J Microencapsul; 1989; 6(1):29-34. PubMed ID: 2565955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
    Wasan KM; Wasan EK; Gershkovich P; Zhu X; Tidwell RR; Werbovetz KA; Clement JG; Thornton SJ
    J Infect Dis; 2009 Aug; 200(3):357-60. PubMed ID: 19545212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
    Everlien H; Hockertz S
    Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation development of freeze-dried oligonucleotide-loaded gelatin nanoparticles.
    Zillies JC; Zwiorek K; Hoffmann F; Vollmar A; Anchordoquy TJ; Winter G; Coester C
    Eur J Pharm Biopharm; 2008 Oct; 70(2):514-21. PubMed ID: 18582569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of an intravenous injectable nimodipine nanosuspension in mice.
    Xiong R; Lu W; Yue P; Xu R; Li J; Chen T; Wang P
    J Pharm Pharmacol; 2008 Sep; 60(9):1155-9. PubMed ID: 18718118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Importance of drug carriers in the treatment of visceral leishmaniasis].
    Fusai T; Durand R; Boulard Y; Paul M; Bories C; Rivollet D; Houin R; Deniau M
    Med Trop (Mars); 1995; 55(1):73-8. PubMed ID: 7637615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical trial of oral dehydroemetine in opisthorchiasis.
    Muangmanee L; Aswapokee N; Jaroonvesama N; Viranuvatti V
    Southeast Asian J Trop Med Public Health; 1974 Dec; 5(4):581-5. PubMed ID: 4617315
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatopulmonary amoebiasis. Efficacy of various treatment regimens containing dehydroemetine and/or metronidazole.
    Jain NK; Madan A; Sharma TN; Sharma DK; Mandhana RG
    J Assoc Physicians India; 1990 Apr; 38(4):269-71. PubMed ID: 2202709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trifluralin liposomal formulations active against Leishmania donovani infections.
    Carvalheiro M; Jorge J; Eleutério C; Pinhal AF; Sousa AC; Morais JG; Cruz ME
    Eur J Pharm Biopharm; 2009 Feb; 71(2):292-6. PubMed ID: 18761404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Freeze drying of human serum albumin (HSA) nanoparticles with different excipients.
    Anhorn MG; Mahler HC; Langer K
    Int J Pharm; 2008 Nov; 363(1-2):162-9. PubMed ID: 18672043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visceral leishmaniasis in the BALB/c mouse: a comparison of the in vivo activity of five non-ionic surfactant vesicle preparations of sodium stibogluconate.
    Williams DM; Carter KC; Baillie AJ
    J Drug Target; 1995; 3(1):1-7. PubMed ID: 7655816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of cyclosporine-loaded poly-sigma-caprolactone nanoparticles.
    Molpeceres J; Aberturas MR; Chacón M; Berges L; Guzmán M
    J Microencapsul; 1997; 14(6):777-87. PubMed ID: 9394259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis.
    Ye J; Wang Q; Zhou X; Zhang N
    Int J Pharm; 2008 Mar; 352(1-2):273-9. PubMed ID: 18054182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Freeze-dried nifedipine-lipid nanoparticles with long-term nano-dispersion stability after reconstitution.
    Ohshima H; Miyagishima A; Kurita T; Makino Y; Iwao Y; Sonobe T; Itai S
    Int J Pharm; 2009 Jul; 377(1-2):180-4. PubMed ID: 19446623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis.
    Sundar S; Goyal AK; Mandal AK; Makharia MK; Singh VP; Murray HW
    J Assoc Physicians India; 1999 Feb; 47(2):186-8. PubMed ID: 10999086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and evaluation of novel itraconazole-loaded intravenous nanoparticles.
    Chen W; Gu B; Wang H; Pan J; Lu W; Hou H
    Int J Pharm; 2008 Oct; 362(1-2):133-40. PubMed ID: 18585448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Freeze-drying of oleanolic acid-loaded nanosuspensions].
    Zhao XL; Chen HB; Chen YJ; Yang XL
    Zhongguo Zhong Yao Za Zhi; 2007 Sep; 32(18):1874-6. PubMed ID: 18051893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro study of the anti-leishmanial activity of biodegradable nanoparticles.
    Venier-Julienne MC; Vouldoukis I; Monjour L; Benoit JP
    J Drug Target; 1995; 3(1):23-9. PubMed ID: 7655817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
    Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
    Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.